Chemomab Therapeutics (NASDAQ:CMMB) Trading Up 0.5% – Should You Buy?

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) shares were up 0.5% on Wednesday . The stock traded as high as $2.19 and last traded at $2.08. Approximately 217,347 shares were traded during trading, an increase of 108% from the average daily volume of 104,315 shares. The stock had previously closed at $2.07.

Analyst Ratings Changes

Separately, Oppenheimer reissued an “outperform” rating and issued a $11.00 price objective (down previously from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th.

Chemomab Therapeutics Stock Down 5.3 %

The firm has a market capitalization of $28.43 million, a price-to-earnings ratio of -1.98 and a beta of 0.66. The stock’s fifty day moving average is $1.93 and its two-hundred day moving average is $1.66.

Hedge Funds Weigh In On Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Sphera Funds Management LTD. purchased a new stake in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned about 8.46% of Chemomab Therapeutics as of its most recent filing with the Securities and Exchange Commission. 46.05% of the stock is owned by institutional investors and hedge funds.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).